Initial Pre-clinical studies focusing on hematological cancers, targeting CD22 or CD33 in lymphoma and acute myeloid leukemia (AML), respectively, demonstrated promising anti-tumor activity (14, 22). This evidence concerns the gene CD22 and acute myeloid leukemia.